Summarized by Masters of Longevity from PR Newswire.
A low-dose repositioned drug enhanced radiotherapy responses without added toxicity.
Key Takeaways
- VS-101 is a low-dose radiosensitizer that weakens RAD51.
- A Phase 1 trial reported complete remissions in seven patients.
- Phase 2 trials are testing VS-101 with chemoradiation without added toxicity.